Carnation Therapeutics Inc

About Carnation Therapeutics Inc

Our History

Carnation Therapeutics Inc was founded in 2021 with the goal of developing new biotech products and therapies for cancer and with the ultimate goal of improving patient care. Our goal is to grow into a leading biotech company with a reputation for innovation and excellence.

Our Technology

We harness the power of antisense oligonucleotides which have emerged as a promising class of therapeutic agents for treating various diseases. These molecules are designed to interact with messenger RNA (mRNA) and modulate protein expression, providing a novel approach to disease treatment.

Tackling few cancers at a time

Lung cancer is a global health crisis, affecting millions of people worldwide. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer deaths, accounting for approximately 1.8 million deaths annually (19.4% of all cancer deaths). The WHO also estimates that 228,840 new cases of lung cancer are diagnosed every year. The stark reality is that lung cancer claims more lives than breast, prostate, and colon cancers combined. Despite advances in cancer research, lung cancer remains a highly aggressive and difficult-to-treat disease, with a five-year survival rate of only around 21%. The need for a cure is urgent, as current treatments often come with harsh side effects and limited success. However, there is hope on the horizon: Carnation Therapeutics Inc's innovative antisense oligonucleotide-based therapy offers promising potential for a lung cancer cure, bringing new hope to patients and their families.

Melanoma is a growing global health concern, affecting over 320,000 people worldwide each year. According to the American Cancer Society, melanoma is the deadliest form of skin cancer, responsible for over 10,000 deaths annually in the United States alone. Despite advances in cancer research, melanoma remains a highly aggressive and difficult-to-treat disease, with a five-year survival rate of only around 20%. The need for a cure is urgent, as current treatments often come with harsh side effects and limited success. However, there is hope on the horizon: Carnation Therapeutics Inc's innovative antisense oligonucleotide-based therapy offers promising potential for a melanoma cure, bringing new hope to patients and their families.

Targeting Cancer's Code: Unlocking New Hope with Anti-Sense Therapies

About Carnation Therapeutics Inc

Our History

Our Technology

Transforming the Future of Cancer Therapy

Tackling few cancers at a time

Contact Us

We would love to hear from you.

Carnation Therapeutics Inc

Drop us a line!

Targeting Cancer's Code: Unlocking New Hope with Anti-Sense Therapies

About Carnation Therapeutics Inc

Our History

Our Technology

Transforming the Future of Cancer Therapy

Tackling few cancers at a time

Contact Us

We would love to hear from you.

Carnation Therapeutics Inc

Drop us a line!

This website uses cookies.